US FDA declares Shire's Firazyr effective, safe for HAE ahead of panel
This article was originally published in Scrip
Executive Summary
Ahead of a 23 June US FDA advisory committee meeting, agency drug reviewers said Shire's Firazyr (icatibant) significantly provided symptom relief from skin and abdominal attacks associated with hereditary angioedema (HAE), a rare, potentially life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein.